Weak SOPHIA OS Signal Dampens Enthusiasm For MacroGenics’ Margetuximab
Executive Summary
Whether MacroGenics’ margetuximab can produce an overall survival benefit from the SOPHIA study could be key to its commercial fortunes, say analysts. The company remains optimistic.
You may also be interested in...
Lackluster Survival Data Likely To Marginalize MacroGenics’ Margenza
While the general lack of an overall survival benefit for MacroGenics’ drug in later-line breast cancer was not surprising, OS data were seen as important for commercial uptake of the drug.
Seattle Genetics Poised For Big Breast Cancer Launch On Positive Tucatinib Data
The company expects to file an NDA for tucatinib in the first quarter after a pivotal trial showed a significant improvement in PFS and OS for patients with advanced or metastatic HER2-positive breast cancer, including those with brain metastases.
10 Approvals To Look Out For In Q3 2023
The third quarter could bring US approvals for a range of novel drugs, including the first treatment for a common eye disease, the first US approval of PD-1/L1 inhibitor from a Chinese firm, and the first oral therapy for postpartum depression.